Christopher Astle, SVP & Chief Financial Officer at Zymeworks Inc. (ZYME), sold 887 shares at $6.01 ($5K) on 2022-12-12, disclosed to the SEC on 2022-12-23.
Scheduled sale ($5k) by SVP & Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |